Page 5 - Cor Pharma News Today

CinCor Pharma Inc (NASDAQ:CINC – Get Rating) shares gapped down before the market opened on Wednesday following a dissappointing earnings announcement. The stock had previously closed at $15.77, but opened at $15.01. CinCor Pharma shares last traded at $14.98, with a volume of 1,078 shares traded. The company reported ($15.71) EPS for the quarter, missing […]

22.03.2022 - BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. ...

03.03.2022 - BOSTON, March 03, 2022 (GLOBE NEWSWIRE) - CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, ...

Should you add these stocks to your portfolio?

With the technology-centric Nasdaq having a rough time of things, this sets up possible attractive discounts for stocks to buy.

CinCor Pharma Appoints June Lee to Its Board of Directors - read this article along with other careers information, tips and advice on BioSpace

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing...

03.01.2022 - BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) - CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, ...

BioSpace Mover & Shakers, Oct. 22 - read this article along with other careers information, tips and advice on BioSpace

BioSpace Mover & Shakers, Oct. 22 - read this article along with other careers information, tips and advice on BioSpace